<DOC>
	<DOC>NCT00239642</DOC>
	<brief_summary>Comparison of three potential iron sucrose maintenance regimens in pediatric chronic kidney disease (CKD) patients</brief_summary>
	<brief_title>Safety and Efficacy of Iron Sucrose in Children</brief_title>
	<detailed_description>Randomized, controlled, open label trial of pediatric CKD patients on stable erythropoietin (EPO) therapy. Patients will be followed for 12 weeks to assess safety (incidence of adverse events) and efficacy (clinical success)</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide, saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Patients between 2 to 21 years of age Patients on stable hemodialysis (HD) or peritoneal dialysis (PD) regimen for 3 months for ≥ 3 months Nondialysis dependent (NDD) patients with glomerular filtration rate (GFR) &lt;60 Hemoglobin (Hgb) ≥ 11g/dL to ≤ 13.5g/dL Ferritin ≤ 800 ng/mL Transferrin saturation (TSAT) ≥ 20% to ≤ 50% Received stable erythropoietin (EPO) regimen for ≥ 8 weeks prior to the qualifying screening visit Known hypersensitivity to iron sucrose Severe diseased of the liver, cardiovascular system, or hemopoietic system Serious infection requiring hospitalization Significant blood loss within the last 3 months Bleeding disorders Pregnancy / Lactation Actively being treated for asthma Hemoglobinopathy Receiving a myelosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Iron</keyword>
	<keyword>Anemia</keyword>
	<keyword>CKD</keyword>
</DOC>